KYNAPID™ Atrial Fibrillation Injection Approvable

Cardiome Pharma Corp. and its co-development partner Astellas Pharma US, Inc. (“Astellas”) announced they have received an approvable action letter from the FDA for KYNAPID™ (vernakalant hydrochloride) Injection for the treatment of atrial fibrillation (AF), Medical News Today reports. Atrial Fibrillation is a potentially life-threatening condition occurring when electrical signals in the heart malfunction.

Latest posts by admin aapc (see all)

Read the complete Article

Login as a member or sign up for free to get uninterrupted access to AAPC blog posts and stay updated on industry news through our monthly newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *